Cycloheximide

Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, May 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PD, Senior, Investment, Abbott Laboratories, DHEAS, G&A, A4, Patient, Risk, Androstenedione, Research and development, R, SVP, Disease, University, Keck School of Medicine of USC, Clinical trial, Glucocorticoid, CAH, Spruce, Pharmacokinetics, Astex Pharmaceuticals, Growth, Biostatistics, Safety, Puberty, Statistics, Business operations, Adrenocorticotropic hormone, Public health, Administration, PCOS, Adolescence, GBT, ACTH, Therapy, Pfizer, Congenital adrenal hyperplasia, Medicine, Drug, Woman, PES, Annual general meeting, Public expenditure, Novartis, GPC Biotech, Strategic partnership, Female, Pharmaceutical industry, Nursing, Adult, Cycloheximide, Pediatrics, Biometrics, Probability

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.
  • “I am pleased by the meaningful progress Spruce made across our clinical and business objectives in the first quarter of 2023.
  • Additionally, we have completed enrollment in our P.O.W.E.R study for PCOS and will be reporting topline data in the third quarter," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.
  • Spruce remains on track to report topline data from adolescents (cohorts 1 and 2) in the second half of 2023.

Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, March 16, 2023
Biotechnology, General Health, Pharmaceutical, Health, Investment, Silicon Valley Bank, PCOS, Strategic partnership, Depreciation, Trial of the century, Androstenedione, Novo Holdings A/S, Public expenditure, CAH, Administration, Polycystic ovary syndrome, Patient, G&A, Spruce, Safety, A4, Research and development, R, Pharmaceutical industry, Cryptocurrency, Adult, HealthCap, Cycloheximide

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.
  • “In 2022, we made significant progress across the board heading into 2023, which we believe will be a pivotal year for Spruce,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.
  • Stock-based compensation expense for the year ended December 31, 2022 was $3.6 million compared to $4.0 million in 2021.
  • Net Loss: Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021.

CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

Retrieved on: 
Sunday, January 8, 2023
Primary sclerosing cholangitis, PBC, Primary biliary cholangitis, Therapy, Patient, Pharmaceutical industry, Cycloheximide

NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (“CymaBay” or the “Company”) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the development and commercialization in Japan of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis (“PBC”).

Key Points: 
  • Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market seladelpar in Japan for PBC.
  • Kaken will be responsible for development, regulatory approval and commercialization of seladelpar in Japan.
  • “Kaken is a well-regarded leader in development and commercialization in Japan with a proud history of scientific and medical innovation.
  • “With this collaboration, we hope we can help improve the lives of patients with cholestatic liver disease in Japan.”

Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, Pharmaceutical, Health, ASEAN, Partnership, CAH, Spruce, Tokyo Stock Exchange, Patient, Pharmaceutical industry, Cycloheximide

Kaken will be responsible for the clinical development and commercialization of tildacerfont in Japan, and Spruce will retain all rights to tildacerfont in all other geographies.

Key Points: 
  • Kaken will be responsible for the clinical development and commercialization of tildacerfont in Japan, and Spruce will retain all rights to tildacerfont in all other geographies.
  • Kaken will also be responsible for securing and maintaining regulatory approvals necessary to market and sell tildacerfont in Japan.
  • “We are excited to enter into this strategic partnership with Kaken Pharmaceutical designed to accelerate our global development plans and bring tildacerfont to patients in Japan who suffer from CAH,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.
  • “As a specialty pharmaceutical company with a strong presence in Japan, Kaken is the ideal strategic partner for the territory, and supports Spruce’s partnering strategy to develop tildacerfont in markets outside of the United States.

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 15, 2022
Insurance, Trial of the century, Time, Research, Conference, Forgiveness, EDT, LRRK2, MAD, Atopic dermatitis, U.S. Securities and Exchange Commission, New Drug Application, Policy, Intellectual property, NDA, Cycloheximide, Autoimmunity, Acquisition, DYRK1A, Private Securities Litigation Reform Act, Income, Inflammation, COVID-19, Leadership, BBI, Next, Investor, TTK, Patient, Stimulator of interferon genes, Therapy, Nasdaq, SAD, Annual general meeting, American Academy, AD, Janus kinase inhibitor, Pharmacokinetics, Rheumatoid arthritis, GLOBE, Humanitarian use licenses, Safety, CLK, Company, Part, Pharmaceutical industry, Vaccine, Video game, Lithium, Brickell

BOULDER, Colo., March 15, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • Revenue was $104.0thousand for the fourth quarter of 2021, compared to $27.0thousand for the fourth quarter of 2020.
  • Research and development expenses were $3.1million for the fourth quarter of 2021, compared to $4.6million for the fourth quarter of 2020.
  • General and administrative expenses were $3.3million for the fourth quarter of 2021, compared to $2.9million for the fourth quarter of 2020.
  • Brickells net loss was $6.1million for the fourth quarter of 2021 compared to $7.4million for the fourth quarter of 2020.

Asset Value Investors (AVI) Submits Modest Proposals to SK Kaken as a Test of Company’s Motivation to Improve Performance and Share Price

Retrieved on: 
Thursday, May 20, 2021
Consulting, Other Professional Services, Professional services, Finance, Cycloheximide, Fungicides, Ketones, Nippon Paint, Chemistry, Physical sciences, Industry economics)

In comparison to more aggressive and dynamic competitors in the industry, SK Kaken is falling behind.\nThis reflects a lack of urgency and weak management discipline, a symptom of a company with a controlling shareholder.

Key Points: 
  • In comparison to more aggressive and dynamic competitors in the industry, SK Kaken is falling behind.\nThis reflects a lack of urgency and weak management discipline, a symptom of a company with a controlling shareholder.
  • This will create greater liquidity and open the company to investment by retail investors, who are now effectively excluded.\n2) Cancel 90% of its treasury shares.
  • Source, Capital IQ.\n2 For FY3/21, SK Kaken achieved operating profits of Y9,942m compared to Y9,140m in FY3/11, a 9% growth.
  • Over the same period, Nippon Paint and Kansai Paint achieved 444% and 48% profit growth respectively.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210520005457/en/\n'